Učitavanje...
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...
Spremljeno u:
| Izdano u: | Cancer Lett |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/ https://ncbi.nlm.nih.gov/pubmed/25458954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|